文献速递免疫规划传染病防控与疫情报告

单剂BNT162b2疫苗在60岁以下人群中产生血清转换

Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort.
PubMed 文献 · Vaccine · 2021-10-23

本研究回顾性分析1898名接种第一剂BNT162b2疫苗者的血清学结果,其中81%在接种后第21天检测。第21天血清阳性率为92.7%,女性阳性率高于男性,年龄>60岁与血清阳性可能性降低相关,接种至检测间隔延长与阳性可能性增加相关。结论提示60岁以下人群单剂接种后高血清转换率或可支持延迟第二剂接种。

要点

  • 第21天血清阳性率达92.7%,总体阳性率86.8%。
  • 女性血清阳性率88.3%高于男性83.3%(p<0.001)。
  • 年龄>60岁与血清阳性可能性降低相关(OR 0.926)。

核心结论

  • 60岁以下人群接种第一剂BNT162b2后血清转换率高,可能支持延迟第二剂接种以缓解疫苗供应短缺。

研究设计与样本

  • 回顾性研究,对1898名接种第一剂BNT162b2疫苗者进行血清学检测,分析血清转换与年龄、性别的关系。

主要发现

  • 第21天检测的血清阳性率为92.7%,总体阳性率为86.8%。
  • 血清阳性率随接种后时间增加:1-14天为2.5%,14-20天为89.8%,21天为92.7%,>21天为95.9%。
  • 第一剂后21天平均抗体水平为64.3 ± 33.01 AU/ml(范围15-373 AU/ml,中位数61 AU/ml)。
  • 女性血清阳性率88.3%高于男性83.3%(p < 0.001;OR 1.515;95% CI 1.152-1.994)。
  • 年龄>60岁与血清阳性可能性降低相关(p < 0.001;OR 0.926;95% CI 0.911-0.940);接种至检测间隔延长与血清阳性可能性增加相关(p < 0.001;OR 1.350;95% CI 1.298-1.404)。

临床怎么用

  • 在疫苗供应紧张时,可参考60岁以下人群单剂接种后高血清转换率的数据,评估延迟第二剂接种的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has led to worldwide vaccination development efforts. In December 2020 the Pfizer BNT162b2 vaccine was approved in the United States. This study describes the first BNT162b2 vaccine dose effect on a large cohort. METHODS: This retrospective study examined first vaccine dose effect on serology and investigated the associations between seroconversion and age or sex. RESULTS: Serological blood tests were performed on 1898 participants following first vaccine dose; 81% were tested on day 21, before receiving the second dose (mean age 47.5 ± 12.45; median 47.7, range 18-90). Positive serology was found in 92.7% of day 21 tests. Overall positivity was 86.8%, with rates increasing from 2.5% within 1-14 days to 89.8% (14-20 days), 92.7% (21 days), and 95.9% (>21 days). Mean antibody levels 21 days after first dose were 64.3 ± 33.01 AU/ml, (range 15-373 AU/ml, median 61 AU/ml). Seropositivity was greater in females than males (88.3%. vs 83.3% respectively, p < 0.001; OR1.515; 95% CI 1.152-1.994). Older age > 60 years was associated with decreased likelihood of seropositivity (p < 0.001; OR 0.926; 95% CI 0.911-0.940). Longer time between first vaccination and serology tests was associated with increased likelihood for seropositivity (p < 0.001; OR 1.350; 95% CI 1.298-1.404). CONCLUSIONS: The high seroconversion rate following first BNT162b2 dose among individuals < 60 may justify delayed delivery of the second dose, potentially help relieve the worldwide vaccination supply shortage, enable vaccination of twice this population within a shorter period, and ultimately reduce COVID-19 contagion.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shachor-Meyouhas Y, Hussein K, Szwarcwort-Cohen M, et al. Single BNT162b2 vaccine dose produces seroconversion in under 60 s cohort. Vaccine. 2021. PMID: 34702617. doi:10.1016/j.vaccine.2021.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。